Characterization of the APP <sup>SAA</sup> mouse model for use in preclinical testing of Alzheimer's disease therapeutics
The APP<sup>SAA</sup> model is a more translationally relevant model than transgenic overexpression models for studying early onset amyloidosis and microglial activation, and is available without legal restrictions. Here we demonstrate key assays and appropriate ages/disease stages for preclinical testing.
Authors
- Ritesh Chidambaram (ORCID: https://orcid.org/0009-0001-1797-1191)
- Sean-Paul G. Williams (ORCID: https://orcid.org/0000-0002-5680-7730)
- Dylan Garceau
- T. Ragan
- Michael Sasner (ORCID: https://orcid.org/0000-0002-6612-6111)
- Ravi S. Pandey (ORCID: https://orcid.org/0000-0001-9567-2851)
- Asli Uyar
- Adrian L Oblak
- Stacey J Sukoff Rizzo
- Nick Ryan
- Gregory W Carter
- Amber Sanders
Institutions
- University of Pittsburgh (US)
- TissueVision (United States) (US)
- Jackson Laboratory (US)
- Indiana University School of Medicine
- Indiana University – Purdue University Indianapolis (US)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70855_105192
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00